Year: 2026
Type: dissertation
Abstract: Kinesin superfamily motor proteins are ATP-driven molecular machines that hydrolyze ATP to move along microtubules and play pivotal roles in intracellular trafficking, spindle formation, and chromosome segregation. By converting chemical energy into mechanical work, these nanomachines drive essential physiological processes in both animal and plant cells, including mitosis, organelle positioning, vesicle transport, and intracellular signaling. Among these motors, the mitotic kinesin Eg5 (KIF11) is of particular importance. During interphase, Eg5 participates in organelle movement, such as endoplasmic reticulum dynamics, and in vesicular transport, including neurotransmitter trafficking from neuronal cell bodies to synapses. During mitosis, Eg5 assembles into a bipolar homotetramer that crosslinks and slides antiparallel microtubules during prometaphase, thereby promoting bipolar spindle formation and accurate chromosome congression. Owing to its essential role in cell division, Eg5 is indispensable for cell viability and is frequently upregulated in cancer cells, making it an attractive target for anticancer therapeutics. A distinctive structural feature of Eg5 is its unusually long loop 5 (L5; 18 residues), which undergoes conformational rearrangements upon nucleotide binding and neck linker docking. Together with the α2 and α3 helices, L5 forms a hydrophobic allosteric pocket that is absent in most other kinesins. This pocket provides a selective binding site for small-molecule inhibitors. Compounds such as monastrol, ispinesib, and S-trityl-L-cysteine (STLC) bind to this site, stabilize specific L5 conformations, and inhibit ATPase activity, microtubule binding, and spindle dynamics, ultimately leading to mitotic arrest (1). Despite their chemical diversity, these inhibitors share a common mechanism of action through exploitation of the functional importance of the L5 pocket. In contrast, other inhibitors such as PVZB1194 and BRD9876 act via alternative allosteric pockets formed by the α4 and α6 helices, highlighting the mechanistic diversity of Eg5 inhibition. In our laboratory, photoswitchable Eg5 inhibitors were previously developed by incorporating azobenzene or spiropyran moieties into known inhibitor scaffolds. These compounds undergo reversible, light-induced conformational changes, enabling optical ON/OFF control of Eg5 ATPase activity in vitro (2). This approach is based on the concept of chromism, in which external stimuli induce reversible structural and functional changes. While thermal or pH-based switching is unsuitable for protein systems due to denaturation risks, light provides a non-invasive and highly precise regulatory tool. Indeed, photochromic compounds such as azobenzene and spiropyran share structural similarities with potent Eg5 inhibitors and enable reversible functional control. Photoresponsive inhibitors and related analogs, including Azo-EMD, have demonstrated cellular efficacy, where light-dependent conformational switching induced monopolar spindle formation and mitotic arrest in HeLa cells, as previously reported by Impastato et al. However, translation of this strategy to whole organisms remains challenging due to limitations in light penetration and delivery. As a preliminary finding to address this limitation, I turned to the transparent nematode Caenorhabditis elegans, which offers optical access to internal tissues, a short life cycle, and well-characterized genetics. C. elegans expresses BMK-1 (KLP-16), a BimC-type kinesin that, although non-essential for mitosis, functions during embryogenesis by suppressing spindle elongation through microtubule crosslinking and opposition of cortical pulling forces (Maia et al.). Importantly, BMK-1 possesses a long L5 comparable to that of Eg5, suggesting that Eg5-specific inhibitors may act on BMK-1 through a conserved L5–α2–α3 allosteric mechanism. Despite BMK-1 being considered a homolog of Eg5 in C. elegans, its biochemical properties and sensitivity to the potent Eg5 inhibitor STLC had not been clearly characterized, leaving the feasibility of in vivo Eg5 control unresolved. To address this gap, I expressed the motor domain of BMK-1 in Escherichia coli and performed its biochemical characterization. BMK-1 exhibited enzymatic properties similar to Eg5, albeit with lower microtubule affinity. Notably, due to the native long Loop 5, wild-type BMK-1 was inhibited by STLC, whereas an L5-shortened mutant (BMK-1SL5) lost STLC sensitivity while retaining microtubulestimulated ATPase activity. Attempts to elucidate the inhibitory mechanism using mixed-motor motility assays were inconclusive, likely due to the low microtubule affinity of BMK-1. Consequently, I shifted to kinetic analyses by generating an F334W BMK-1 variant, introducing a tryptophan residue absent in the wild-type protein. Fluorescence resonance energy transfer (FRET) experiments using mant-ATP revealed that STLC inhibits ADP release, consistent with the inhibition mechanism previously established for Eg5. These results demonstrate that BMK-1 and Eg5 share an L5-dependent inhibition pathway, providing mechanistic evidence that BMK-1 can serve as an in vivo-compatible model for evaluating Eg5 inhibitors. However, because BMK-1 does not directly drive spindle assembly in C. elegans, its utility for studying mitotic inhibition is limited. To overcome this limitation, I subsequently focused on KLP-18, a mitotic kinesin essential for bipolar spindle assembly in C. elegans. Although the inhibitory effects were less pronounced than those observed for Eg5 and BMK-1, my results indicate that the long L5–mediated enhancement of sensitivity to Eg5-specific inhibitors is also conserved in KLP-18. Taken together, this line of research suggests that elongation of loop 5 represents a general strategy for increasing sensitivity to Eg5-specific allosteric inhibitors such as STLC. This principle may be extendable to other kinesins, including kinesin-1, through rational manipulation of L5 length and composition. These findings provide foundational biochemical data for the development of light-controllable kinesin systems and establish a framework for photo-regulation of Eg5 activity in vivo, beginning with C. elegans as a model organism. Ultimately, this approach may contribute to the long-term development of optically controlled kinesintargeted pharmacological strategies with potential relevance to human therapeutics.
Authors: Fofou Yonta, Tostani, フォフー ヨンタ, トスタニ
Language: English
Subfield: Cell Biology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W7162722129
